Collagen-induced platelet activation pathway

The collagen-induced platelet activation pathway is a fundamental biological process that initiates thrombus formation following blood vessel injury. It begins when platelets adhere to exposed subendothelial collagen via the Glycoprotein VI (GPVI) receptor and the integrin alpha-2/beta-1 complex [1, 2]. GPVI acts as the primary signaling receptor, utilizing an immunoreceptor tyrosine-based activation motif (ITAM) to recruit and activate Src family kinases and Spleen tyrosine kinase (Syk) [1]. This signaling cascade activates Phospholipase C gamma 2 (PLCγ2), leading to intracellular calcium release, platelet shape change, and the secretion of pro-thrombotic mediators like ADP and thromboxane A2 [3]. These mediators amplify the response, leading to the activation of integrin alpha-IIb/beta-3 and subsequent platelet aggregation [2]. While essential for normal hemostasis, overactivation of this pathway is a key driver of arterial thrombosis in diseases such as myocardial infarction and stroke [4]. Modern therapeutic approaches, including GPVI-targeting antibodies like Glenzocimab and soluble GPVI decoys like Revacept, are being developed to inhibit this pathway selectively [5, 6].

Other names

Collagen-mediated platelet activationGPVI signaling pathwayPlatelet collagen receptor signaling

Glycoprotein VI antagonism, Cyclooxygenase-1 inhibition, P2Y12 receptor antagonism